A Post-Authorization Safety Surveillance Study to Report Clinical Experience with Purified Factor IX Concentrate in Pediatric Patients with Hemophilia B
Zoran Igrutinović,1,2 Hélène Louise Hooimeijer,3 Karim Kentouche,4 Jaco Botha,5 Peter L Turecek,6 Marta Kokot-Kierepa,5 Hanna T Gazda7 1Clinic of Pediatrics, Department of Hemato-Oncology, University Clinical Center of Kragujevac, Kragujevac, Serbia; 2Faculty of Medical Sciences, Departme...
Main Authors: | Igrutinović Z, Hooimeijer HL, Kentouche K, Botha J, Turecek PL, Kokot-Kierepa M, Gazda HT |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2024-03-01
|
Series: | Journal of Blood Medicine |
Subjects: | |
Online Access: | https://www.dovepress.com/a-post-authorization-safety-surveillance-study-to-report-clinical-expe-peer-reviewed-fulltext-article-JBM |
Similar Items
-
Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Untreated Patients with Hemophilia B
by: Richard Lemons, et al.
Published: (2024-01-01) -
Real‐world experience of rIX‐FP prophylaxis at dosing intervals of up to 14 days in a pediatric patient with hemophilia B during the COVID‐19 pandemic
by: Bolívar Luis Díaz‐Jordán, et al.
Published: (2023-12-01) -
New developments in the management of moderate-to-severe hemophilia B
by: Nazeef M, et al.
Published: (2016-04-01) -
Excellent hemostatic control during cardiac surgery in a patient with hemophilia B treated with albutrepenonacog alfa (rIX‐FP): A case report
by: Francisco José López‐Jaime, et al.
Published: (2023-06-01) -
Identification and Genetic Analysis of a Factor IX Gene Intron 3 Mutation in a Hemophilia B Pedigree in China
by: Dong Hua Cao, et al.
Published: (2014-08-01)